Skip links

Evidence Library  /  Condition guides

Condition guide · Dogs, cats and horses

Antibiotic-resistant keratitis: where UVC fits.

A guide for veterinary teams

34%

of canine keratitis isolates were multidrug-resistant in 2020, up from 5% in 2016 (US study, 476 dogs)

0

bacterial growth in mouse corneas infected with multi-drug-resistant Pseudomonas after UVC

5 s

of 265 nm UVC worked as well against MRSP and MDR E. coli as against susceptible strains in vitro

Multidrug-resistant bacteria are increasingly found in corneal infections, especially in referral cases. UVC acts on microbial DNA directly, so its effect doesn’t depend on antibiotic susceptibility, and published studies show it working against resistant strains.

What it is.

Bacterial keratitis in companion animals is most often caused by Staphylococcus pseudintermedius, β-haemolytic streptococci and Pseudomonas aeruginosa. A 2026 review in Veterinary Ophthalmology describes multidrug-resistant strains as increasing, especially in referral and specialty clinics, and calls resistance a current, clinically significant problem rather than a future risk.

Why it’s hard to treat.

  • In a Midwestern US study of 476 dogs, multidrug resistance among isolates rose from 5% in 2016 to 34% in 2020. Staphylococci were the most often resistant (33%).
  • Animals recently treated with topical antimicrobials are more likely to carry resistant bacteria.
  • Standard susceptibility testing is based on systemic drug levels, so lab results may not predict how eye drops perform on the ocular surface.
  • Culture results take days, so first-line treatment is empirical.

Where UVC fits.

UVC damages microbial DNA directly, so the resistance mechanisms that defeat antibiotics don’t protect bacteria from it. In mice with keratitis caused by a multi-drug-resistant Pseudomonas strain, UVC cleared the infection as effectively as the one antibiotic the strain was susceptible to. An independent Royal Veterinary College study using a prototype 265 nm device found 5-second exposures worked as well against MRSP and multidrug-resistant E. coli as against susceptible strains. In the 2026 clinical study, one 5-second PhotonUVC treatment cut bacterial load by a median 96.5%. The 2026 review lists ultraviolet-based approaches among the antibiotic-sparing strategies to develop alongside antibiotics.

What the evidence doesn’t show yet.

  • Clinical outcome data, such as healing time and recurrence, in resistant infections are not yet published.
  • The resistant-strain studies were laboratory and mouse studies.
  • UVC treats only the surfaces it reaches, not the conjunctival fornices or deeper tissue.

Sources

About this guide

Written by Photon Therapeutics for veterinary professionals. It summarises published evidence and is not a substitute for clinical judgement. Photon Therapeutics makes the PhotonUVC Vet device.

The evidence.

Independent efficacy study · 2025

Veterinary clinical study · 2026

Laboratory efficacy study · 2025

Back to the Evidence Library

Bring PhotonUVC Vet into your practice.

A 5-second, non-contact UVC treatment for corneal infections in dogs, cats and horses.

See PhotonUVC Vet    Buy PhotonUVC Vet